KP415 Open-Label Safety Study in Children (6-12 Years of Age) With ADHD

Completed · Phase 3

Conditions studied: ADHD

In brief

This study is a multicenter, dose-optimized, open-label safety study with KP415 in children with Attention-Deficit/Hyperactivity Disorder (ADHD).

Key facts

Study ID

NCT03460652

Run by

Zevra Therapeutics

People needed

282

Starts

2018-03-13

Expected to finish

2019-07-09

Last updated by the study team

2021-07-19

Who can join

Age: 6 and older, up to 12. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subject must meet Diagnostic and Statistical Manual of Mental Disorders - Fifth Edition (DSM-5) criteria for a primary diagnosis of ADHD (combined, inattentive, or hyperactive/impulsive presentation) per clinical evaluation and confirmed by the Mini International Neuropsychiatric Interview for Children and Adolescents (MINI-KID).
• Subject must have a score of at least 3 (mildly ill) on the clinician-administered Clinical Global Impressions-Severity (CGI-S) scale.
• Subjects who completed the efficacy study with KP415 may be rolled over into the current study.
• Subject, subject's parent/legal guardian and caregiver (if applicable) must understand and be willing and able to comply with all study procedures and visit schedule.

You may not qualify if…

• Subject with any clinically significant chronic medical condition that may interfere with the participant's ability to participate in the study.
• Subject has any diagnosis of bipolar I or II disorder, major depressive disorder, conduct disorder, obsessive-compulsive disorder, any history of psychosis, autism spectrum disorder, disruptive mood dysregulation disorder (DMDD), intellectual disability, Tourette's Syndrome, confirmed genetic disorder with cognitive and/or behavioral disturbances.
• Subject has evidence of any chronic disease of the central nervous system (CNS) such as tumors, inflammation, seizure disorder, vascular disorder, potential CNS related disorders that might occur in childhood, or history of persistent neurological symptoms attributable to serious head injury.
• Subject has a current (last month) psychiatric diagnosis other than specific phobia, motor skills disorders, oppositional defiant disorder, sleep disorders, elimination disorders, adjustment disorders, learning disorders, or communication disorders. Participants with school phobia or separation anxiety will not be eligible.
• Subject has clinically significant suicidal ideation/behavior, based on a history of attempted suicide and the C-SSRS assessment at Screening or at any time before the last dose of study drug.
• Subject has any clinically significant unstable medical abnormality, chronic disease, or a history of a clinically significant abnormality of the cardiovascular, gastrointestinal, respiratory, hepatic, or renal systems, or a disorder or history of a condition that may interfere with drug absorption, distribution, metabolism, or excretion of study drug.
• Subject has a history or presence of abnormal ECGs.

Where it is running

• Woodland International Research — Little Rock, Arkansas, United States
• MCB Clinical Research Centers — Colorado Springs, Colorado, United States
• Meridien Research — Bradenton, Florida, United States
• Clinical Neuroscience Solutions, Inc. — Jacksonville, Florida, United States
• Innovative Clinical Research, Inc. — Lauderhill, Florida, United States
• Meridien Research — Maitland, Florida, United States
• Clinical Neuroscience Solutions, Inc. — Orlando, Florida, United States
• Capstone Clinical Research — Libertyville, Illinois, United States
• Psychiatric Associates — Overland Park, Kansas, United States
• Center for Psychiatry and Behavioral Medicine, Inc. — Las Vegas, Nevada, United States
• Hassman Research Institute — Berlin, New Jersey, United States
• Neuro-Behavioral Clinical Research — Canton, Ohio, United States
• Midwest Clinical Research Center, LLC — Dayton, Ohio, United States
• Oregon Center for Clinical Investigations, Inc. — Portland, Oregon, United States
• Oregon Center for Clinical Investigations, Inc. — Salem, Oregon, United States
• Clinical Neuroscience Solutions, Inc. — Memphis, Tennessee, United States
• FutureSearch Trials — Austin, Texas, United States
• Bayou City Research, Ltd. — Houston, Texas, United States
• Houston Clinical Trials — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.